<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003702</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0174</org_study_id>
    <secondary_id>NCI-2011-02026</secondary_id>
    <secondary_id>ECOG-G174</secondary_id>
    <secondary_id>CDR0000066809</secondary_id>
    <secondary_id>GOG-0174</secondary_id>
    <secondary_id>GOG-0174</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00003702</nct_id>
  </id_info>
  <brief_title>Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia</brief_title>
  <official_title>A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus &quot;Pulsed&quot; Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      Randomized phase III trial to compare the effectiveness of methotrexate with that of
      dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
      die. It is not yet known whether methotrexate is more effective than dactinomycin in treating
      patients with gestational trophoblastic neoplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Compare the efficacy of methotrexate vs dactinomycin, as measured by complete response
      rate, in patients with low-risk gestational trophoblastic neoplasia.

      II. Compare the toxicity of these regimens in these patients. III. Determine whether the
      definition of persistent gestational trophoblastic neoplasia is accurate (as determined by
      the likelihood that the beta human chorionic gonadotropin [HCG] titer would decline on the
      day treatment is initiated).

      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive methotrexate intramuscularly once weekly in the absence of disease
      progression or unacceptable toxicity.

      ARM II: Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of
      disease progression or unacceptable toxicity. All patients continue on treatment until 1 beta
      human chorionic gonadotropin (HCG) titer is below the institutional normal. Patients then
      receive 1 additional consolidation treatment.

      Patients are followed every 4 weeks for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1999</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay</measure>
    <time_frame>Endpoint was assessed by hCG measurements taken weekly, once normal, treatment was bi-weekly, then monthly, up to 12 months.</time_frame>
    <description>Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0</measure>
    <time_frame>Prior to study entry, weekly during treatment, up to 12 months after normal titer, an average of 7 months.</time_frame>
    <description>Number of participants with a maximum grade of 3 or higher during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Decline of hCG on Day 1 of Treatment</measure>
    <time_frame>Prior to study entry and on Day 1 of treatment</time_frame>
    <description>Number of patients with a decline in hCG on day 1 of treatment relative to the level at enrollment. A decline is defined as a decrease by 1 or more units between enrollment and treatment start.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Good Prognosis Metastatic Gestational Trophoblastic Tumor</condition>
  <condition>Hydatidiform Mole</condition>
  <condition>Non-Metastatic Gestational Trophoblastic Tumor</condition>
  <condition>Uterine Corpus Choriocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (methotrexate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (dactinomycin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dactinomycin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (dactinomycin)</arm_group_label>
    <other_name>Actinomycin A IV</other_name>
    <other_name>Actinomycin C1</other_name>
    <other_name>ACTINOMYCIN D</other_name>
    <other_name>Actinomycin I1</other_name>
    <other_name>Actinomycin IV</other_name>
    <other_name>Actinomycin X 1</other_name>
    <other_name>Actinomycin-[thr-val-pro-sar-meval]</other_name>
    <other_name>Cosmegen</other_name>
    <other_name>DACT</other_name>
    <other_name>Dactinomycine</other_name>
    <other_name>Lyovac Cosmegen</other_name>
    <other_name>Meractinomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Arm I (methotrexate)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven low-risk gestational trophoblastic neoplasia (persistent
             hydatidiform mole or choriocarcinoma), defined as 1 of the following:

               -  Less than 10% decrease in the beta human chorionic gonadotropin (HCG) titer over
                  3 weekly titers

               -  Greater than 20% sustained rise in beta HCG titer over two consecutive weeks

               -  Persistently elevated beta HCG titer more than 4 months after initial curettage
                  (greater than 5 mIU/mL minimum)

               -  Histologically proven nonmetastatic choriocarcinoma

               -  Metastases to vagina, parametria, or lung (if no single pulmonary lesion is
                  greater than 2 cm)

          -  WHO score 0-6 (not including blood group or CT lung)

          -  No histologically confirmed placental site pseudotumor

          -  Must have undergone at least 1 uterine curettage

          -  Previously untreated disease

          -  Performance status - GOG 0-2

          -  WBC at least 3,000/mm^3

          -  Granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  SGPT and SGOT no greater than 3 times ULN

          -  Alkaline phosphatase no greater than 3 times ULN

          -  No significant prior abnormal hepatic function

          -  Creatinine no greater than 2.0 mg/dL

          -  No significant prior abnormal renal function

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for one year after study
             entry

          -  No other prior or concurrent malignancies within the past 5 years except
             nonmelanomatous skin cancer

          -  No prior chemotherapy for gestational trophoblastic neoplasia

          -  No concurrent curettage except as needed to control vaginal bleeding or to rule out
             placental site pseudotumor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Osborne</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>November 2, 2017</results_first_submitted>
  <results_first_submitted_qc>April 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2018</results_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choriocarcinoma</mesh_term>
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
    <mesh_term>Hydatidiform Mole</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Dactinomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial opened to patient accrual on 6/14/1999 and closed to accrual on 2/26/2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Methotrexate 30 mg/m2 IM Weekly</title>
          <description>Arm 1: Methotrexate 30 mg/m2 IM weekly</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks</title>
          <description>Arm 2: Dactinomycin 1.25 mg/m2 IV push every 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible cell types</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet criteria for persistence</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>WHO score &gt; 6</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequate documentation of disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible participants</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Methotrexate 30 mg/m2 IM Weekly</title>
          <description>Arm 1: Methotrexate 30 mg/m2 IM weekly</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks</title>
          <description>Arm 2: Dactinomycin 1.25 mg/m2 IV push every 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="107"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="7.9"/>
                    <measurement group_id="B2" value="30.4" spread="8.6"/>
                    <measurement group_id="B3" value="29.6" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay</title>
        <description>Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements.</description>
        <time_frame>Endpoint was assessed by hCG measurements taken weekly, once normal, treatment was bi-weekly, then monthly, up to 12 months.</time_frame>
        <population>Eligible patients who received a random treatment allocation</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Methotrexate 30 mg/m2 IM Weekly</title>
            <description>Arm 1: Methotrexate 30 mg/m2 IM weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks</title>
            <description>Arm 2: Dactinomycin 1.25 mg/m2 IV push every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay</title>
          <description>Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements.</description>
          <population>Eligible patients who received a random treatment allocation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete/Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inevaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0</title>
        <description>Number of participants with a maximum grade of 3 or higher during the treatment period.</description>
        <time_frame>Prior to study entry, weekly during treatment, up to 12 months after normal titer, an average of 7 months.</time_frame>
        <population>Eligible and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Methotrexate 30 mg/m2 IM Weekly</title>
            <description>Arm 1: Methotrexate 30 mg/m2 IM weekly</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks</title>
            <description>Arm 2: Dactinomycin 1.25 mg/m2 IV push every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0</title>
          <description>Number of participants with a maximum grade of 3 or higher during the treatment period.</description>
          <population>Eligible and treated patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Decline of hCG on Day 1 of Treatment</title>
        <description>Number of patients with a decline in hCG on day 1 of treatment relative to the level at enrollment. A decline is defined as a decrease by 1 or more units between enrollment and treatment start.</description>
        <time_frame>Prior to study entry and on Day 1 of treatment</time_frame>
        <population>Eligible and evaluated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Participants</title>
            <description>Enrolled participants that had a subsequent hCG measurement after enrollment and before treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Decline of hCG on Day 1 of Treatment</title>
          <description>Number of patients with a decline in hCG on day 1 of treatment relative to the level at enrollment. A decline is defined as a decrease by 1 or more units between enrollment and treatment start.</description>
          <population>Eligible and evaluated patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through Study completion, an average of 7 months.</time_frame>
      <desc>The frequencies of any serious adverse event or other adverse events (grade 2 or higher) by category or specific term occurring during treatment and up to 30 days after stopping the study treatment are reported. Adverse events were collected by Organ System Class.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Methotrexate 30 mg/m2 IM Weekly</title>
          <description>Arm 1: Methotrexate 30 mg/m2 IM weekly</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks</title>
          <description>Arm 2: Dactinomycin 1.25 mg/m2 IV push every 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Other Hemotologic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection/Fever</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary/Renal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela M. Kuras on behalf of Virginia Filiaci</name_or_title>
      <organization>NRG Oncology</organization>
      <phone>7168455702</phone>
      <email>kurasa@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

